Carriers of what matters.
1 in 40 couples is at risk of transmitting recessive genetic diseases. Heres carrier screening is a complete solution, compatible and adapted to the needs of each case and that helps parents to have a healthy child.
And it is having adequate information about our genes today that allows us to make the best decisions about tomorrow.
help in decision making
Through a combination of different genetics technologies and the application of cutting-edge bioinformatics, we obtain personalized results with a high compatibility rate, which allows us to accompany and advise our clients:
Gamete donor banks (eggs or sperm).
Assisted reproduction clinics.
Through any of the above, couples who want to discover their carrier status.
Better data, better decisions
Better data, better decisions
With a single sample and a single test, we adapt our solutions to your needs.
Because each case needs a different evaluation, different advice, but the same rigour and quality in the process.
Your needs, our solutions:
Determines donor compatibilities
30 genes are analysed.
Its aim is to identify suitable and unsuitable donors.
It is used to test both Oocyte and Gamete donors.
Once the donor has been assigned to a treatment, another more exhaustive and extensive test must be carried out, but without the need to obtain a new sample.
Determines the compatibility between two people
More than 300 genes are studied.
It is recommended for patients with reproductive problems who undertake IVF treatments with their own or donated gametes. It allows mutations responsible for the most prevalent diseases to be detected, regardless of ethnicity or geographical area.
It reports on variants classified as “pathogenic” or “probably pathogenic”. It also includes all the diseases recommended by the SEF (Spanish Fertility Association), as well as those that, after more than 70,000 tests, turned out to be more prevalent. The results include a “Matching” report of the couple ordonor-recipient.
Allows compatibility with other studios
More than 1200 genes are analysed.
It is recommended for clinics, banks and patients.
It allows for testing the compatibility of results between samples analysed with any carrier test, not just Heres. It offers a clear, understandable diagnosis of high quality and compatibility, without the need to resort to higher costs.
Our path starts here
Your needs are the beginning of a process, ours. Shall we start?
For an optimal sample, two 4 ml tubes in EDTA (lavender stopper) will be necessary.
Blood samples can be shipped at room temperature within 72 hours of collection. Otherwise, the samples must be refrigerated.
This type of sample can be shipped at room temperature within 72-96 hours of collection.
Less than 21 business days after receipt of the sample in the laboratory, the results will be available.
Following the ACMG guidelines for the interpretation of sequence variants, only variants classified as ‘pathogenic’ or ‘probably pathogenic’ are reported.
FullGenomics genetic advisers offer sustained, clear and understandable answers to possible questions raised by the results or the steps to follow after them.
The power to decide better
We know that information is necessary to be able to make decisions, but also that too much of it, or if it is presented in a complicated way, can be incomprehensible or overwhelming. For this reason, our team of genetic advisers, whether you are a parent, donor, clinic or medical professional, is at your disposal throughout the process.
The results are in. And now what?
We will send the clinic a detailed and personalized report with the results, so that the gynaecologist and the patient can better plan decision-making in the reproductive process.
When the test result is positive and, therefore, the same pathological variant is detected:
If it is an incompatibility in a positive matching study between the patient and the donor, the donor must be replaced by another compatible one.
If it is a couple, and both are carriers of the same variant that causes disease, the genetic adviser will inform them of the options available to minimise the risk. Tests such as PGT or prenatal tests such as chorionic villus sampling or amniocentesis will be recommended, which could determine if the baby is or will be affected with the recessive disorde.